Arcturus Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 9, 2022
October 26 2022 - 4:30PM
Business Wire
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”,
Nasdaq: ARCT), a global, late-stage clinical messenger RNA
medicines company focused on the development of infectious disease
vaccines and significant opportunities within liver and respiratory
rare diseases, today announced that it will release its financial
results for the quarter ended September 30, 2022 after the market
close on Wednesday, November 9 and will also host a conference call
and webcast at 4:30 pm Eastern Standard Time on November 9,
2022.
Wednesday, November 9, 2022 @ 4:30 pm EST Domestic:
1-888-204-4368 International: 1-323-994-2093 Conference ID: 2581187
Webcast: Link
About Arcturus Therapeutics
Founded in 2013 and based in San Diego, California, Arcturus
Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global late-stage
clinical mRNA medicines and vaccines company with enabling
technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA
Technology (samRNA) and (iii) mRNA drug substance along with drug
product manufacturing expertise. Arcturus’ diverse pipeline of RNA
therapeutic and vaccine candidates includes mRNA vaccine programs
for SARS-CoV-2 (COVID-19) and Influenza, and other programs to
potentially treat ornithine transcarbamylase (OTC) deficiency, and
cystic fibrosis, along with partnered programs including glycogen
storage disease type III, and hepatitis B virus. Arcturus’
versatile RNA therapeutics platforms can be applied toward multiple
types of nucleic acid medicines including messenger RNA, small
interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and
gene editing therapeutics. Arcturus’ technologies are covered by
its extensive patent portfolio (patents and patent applications
issued in the U.S., Europe, Japan, China and other countries).
Arcturus’ commitment to the development of novel RNA therapeutics
has led to collaborations including, amongst others, Janssen
Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies
of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., and the
Cystic Fibrosis Foundation. In addition, please connect with us on
Twitter and LinkedIn. For more information visit
www.ArcturusRx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221026005361/en/
Arcturus Therapeutics IR@arcturusrx.com
Kendall Investor Relations Carlo Tanzi, Ph.D. (617) 914-0008
ctanzi@kendallir.com
Arcturus Therapeutics (NASDAQ:ARCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arcturus Therapeutics (NASDAQ:ARCT)
Historical Stock Chart
From Apr 2023 to Apr 2024